Literature DB >> 24420328

Recent increases in efficiency in cigarette nicotine delivery: implications for tobacco control.

Thomas Land1, Lois Keithly, Kevin Kane, Lili Chen, Mark Paskowsky, Doris Cullen, Rashelle B Hayes, Wenjun Li.   

Abstract

INTRODUCTION: Recent increases in nicotine yield of cigarettes sold in the United States have been attributed by tobacco manufacturers to natural variation in agricultural products. We tested this assertion using data reported by the manufacturers.
METHODS: Data were collected from the annual reports filed with the Massachusetts Department of Public Health by 4 major manufacturers of cigarettes from 1997 to 2012. Reportable measures included nicotine yield (mg/cig) in smoke generated by a smoking machine based on the Massachusetts smoking regimen and nicotine content in the unburned tobacco per cigarette (mg/cig). We used multilevel linear mixed-effect models to examine temporal trends in and predictors of these measures, overall and by brand style and by brand family.
RESULTS: While nicotine content remained relatively stable in the range of 12-14 mg/cig between 1998 and 2012, average nicotine yield increased significantly (p < .01) over time and ranged from the lowest level of 1.65 mg/cigarette in 1999 to the highest level of 1.89 mg/cigarette in 2011. Nicotine yield and yield-to-content ratio varied significantly among manufacturers and brand families. When controlling for market category and all available design features, the yield-to-content ratio of all manufacturers except Lorillard increased significantly over time.
CONCLUSIONS: The data provided by tobacco manufacturers suggest that the increasing trend in yield is not related to variations in nicotine content but to the yield-to-content ratio, which contradicts their assertions of agricultural variations. Nicotine yield and yield-to-content ratio are controllable features of cigarettes, and they should be monitored and regulated by government agencies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24420328     DOI: 10.1093/ntr/ntt219

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  7 in total

1.  The prevalence of brand switching among adult smokers in the USA, 2006-2011: findings from the ITC US surveys.

Authors:  Monica E Cornelius; K Michael Cummings; Geoffrey T Fong; Andrew Hyland; Pete Driezen; Frank J Chaloupka; David Hammond; Richard J O'Connor; Maansi Bansal-Travers
Journal:  Tob Control       Date:  2014-09-26       Impact factor: 7.552

2.  Electronic cigarette effectiveness and abuse liability: predicting and regulating nicotine flux.

Authors:  Alan Shihadeh; Thomas Eissenberg
Journal:  Nicotine Tob Res       Date:  2014-09-01       Impact factor: 4.244

3.  Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach.

Authors:  Dirk W Lachenmeier; Jürgen Rehm
Journal:  Sci Rep       Date:  2015-01-30       Impact factor: 4.379

4.  Changes in cigarette smoking initiation, cessation, and relapse among U.S. adults: a comparison of two longitudinal samples.

Authors:  Zinan Yi; Maria E Mayorga; Kristen Hassmiller Lich; Jennifer L Pearson
Journal:  Tob Induc Dis       Date:  2017-03-14       Impact factor: 2.600

5.  Nicotine Content in Swedish-Type Snus Sold in Norway From 2005 to 2020.

Authors:  Tord Finne Vedøy; Karl Erik Lund
Journal:  Nicotine Tob Res       Date:  2022-06-15       Impact factor: 5.825

6.  Cigarette Use and Cannabis Use Disorder Onset, Persistence, and Relapse: Longitudinal Data From a Representative Sample of US Adults.

Authors:  Andrea H Weinberger; Jonathan Platt; Jiaqi Zhu; Jacob Levin; Ollie Ganz; Renee D Goodwin
Journal:  J Clin Psychiatry       Date:  2021-06-29       Impact factor: 5.906

7.  Comparative risk assessment of tobacco smoke constituents using the margin of exposure approach: the neglected contribution of nicotine.

Authors:  Claudia Baumung; Jürgen Rehm; Heike Franke; Dirk W Lachenmeier
Journal:  Sci Rep       Date:  2016-10-19       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.